Title: Increase Awareness to Osteopenia/Osteoporosis Treatment of Patients With Prostate Cancer, by Bisphosphonate Therapy - Registry.
N/A
60 Years
N/A
60 Years
N/A
Not Enrolling
Male
Osteoporosis, Prostate Cancer
Male
Osteoporosis, Prostate Cancer
Trial Information
Title: Increase Awareness to Osteopenia/Osteoporosis Treatment of Patients With Prostate Cancer, by Bisphosphonate Therapy - Registry.
Inclusion Criteria:
- Man with Prostate Cancer
- Men ≥70 years old or ≥60 years old treated by LH-RH agonist for at least 2 years or
Man who was diagnosed in the past with Osteopenia/osteoporosis
- Osteopenia/osteoporosis proven by bone density test.
Exclusion Criteria:
- Creatinine clearance < 30ml/min
- Hypercalcemia
- Actual treatment by Bisphosphonate or steroids
- Hypersensibility to Bisphosphonate or any contraindication to its use.
- Metastatic prostate Cancer
- Patients not suitable for compliance.
The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
To evaluate the compliance in male patients with prostate cancer treated with Bisphosphonate and that suffered from Osteopenia/osteoporosis.
Outcome Time Frame:
6 months
Safety Issue:
No
Principal Investigator
Nurit Tweezer
Investigator Role:
Study Director
Investigator Affiliation:
Sanofi-aventis administrative office Israel
Authority:
Israel: Ministry of Health
Study ID:
RISED_L_04261
NCT ID:
NCT00816452
Start Date:
January 2009
Completion Date:
July 2010
Related Keywords:
- Osteoporosis
- Prostate Cancer
- Osteoporosis
- Prostate Cancer
- Osteoporosis in male with Prostate Cancer
- Bone Diseases, Metabolic
- Osteoporosis
- Prostatic Neoplasms
Name | Location |
|---|
